Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | MTOR | P42345 | 1/20 | 0.62 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.62 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.62 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.62 |
| ▸ | NT5E | P21589 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.44 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.42 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3266289 | 0.87 | LMNA (0.64) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL1981224 | 0.86 | LMNA (0.63) | LMNATHRBMTORMDM2NCOA1 | |
| Hydrochloric Acid SCHEMBL6946856 | 0.85 | LMNA (0.62) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL3404713 | 0.84 | LMNA (0.60) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL635860 | 0.84 | LMNA (0.60) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL27267985 | 0.84 | LMNA (0.60) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL3662232 | 0.82 | LMNA (0.59) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL3630055 | 0.82 | LMNA (0.59) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL3867213 | 0.82 | LMNA (0.59) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL3662233 | 0.82 | LMNA (0.59) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585955-A4 | USE OF ISOGENIC HUMAN CANCER CELLS FOR HIGH-THROUGHPUT SCREENING AND DRUG DISCOVERY | UNIV JOHNS HOPKINS (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20050239051-A1 | Use of isogenic human cancer cells for high-throughput screening and drug discovery | THE JOHNS HOPKINS UNIVERSITY (US) | 2005-10-27 | — | — | US | disclosed |
| EP-1585955-A2 | USE OF ISOGENIC HUMAN CANCER CELLS FOR HIGH-THROUGHPUT SCREENING AND DRUG DISCOVERY | The Johns Hopkins University, School of Medicine, Office of Technology Licencing (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20030069256-A1 | Use of isogenic human cancer cells for high-throughput screening and drug discovery | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-04-10 | — | — | US | disclosed |
| WO-2003027632-A2 | USE OF ISOGENIC HUMAN CANCER CELLS FOR HIGH-THROUGHPUT SCREENING AND DRUG DISCOVERY | THE JOHNS HOPKINS UNIVERSITY (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069256-A1 | Use of isogenic human cancer cells for high-throughput screening and drug discovery | TP53, BRCA1, MCL1 | LMNA 4035/4885THRB 2895/4885MTOR 3225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.